Affymetrix Tumor Profiling Grant Program

How do you derive clinically relevant biomarkers?

Systematic tumor profiling with multi-omics tools and rapid analytical validation is a powerful way to discover clinically relevant biomarkers and increase the probability of success.

The parallel analysis of any combination of SNP, copy number variation, gene expression and regulation, protein expression, or cellular analysis enables rapid identification of the most robust biomarkers for impactful clinical application. The data from one type of analyte can provide biological validation for another, enhancing the diagnostic power and increasing confidence in the final biomarkers selected towards routine clinical use.

Affymetrix wants to help

Affymetrix Tumor Profiling Grant Program aims to support translational cancer researchers who are discovering and analytically validating biomarkers that can eventually be used to address unmet clinical needs in cancer treatment.

Affymetrix will award up to three researchers resident in the European Union (“EU”) or Norway, Switzerland, Bahrain, Israel, Jordan, Kuwait, Morocco, Oman, Qatar, Russia, Saudi Arabia, South Africa, Tunisia, Turkey or United Arab Emirates with the tools to measure and validate at least two different analytes—DNA, RNA, proteins, or cells—in 30 tumor samples.

Grant program application criteria

To qualify for Affymetrix Tumor Profiling Grant Program, you must:

• Seek biomarkers that address a significant unmet clinical need.
• Have a plan to validate towards a routine test after the discovery and analytical study.
• Combine the analysis of at least two different molecular or cellular parameters from the following: copy number variation, SNPs, gene or transcript isoform expression, long and small non-coding RNA expression, cytokines, cell surface markers, soluble proteins.
• Have 30 samples (FFPE, fresh frozen tissue, or blood) collected and ready for processing.
• Profile the samples using the most appropriate Affymetrix technology according to manufacturer’s guidelines.
• Generate and interpret preliminary results no later than 30th September 2016, with final data completed no later than 30th December 2016.
• Be willing and able to present data at an Affymetrix-sponsored event no later than 31st May 2017.

Apply today: www.surveymonkey.com/r/AffyTumorGrant_EMEA

Affymetrix Grant Program on Twitter: #AffyTumorGrant

Frank Smith | EMEA Marketing Manager – Oncology & Translational Research, Affymetrix UK Ltd

Stats

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.